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Background.10%ofovarianﬁbromatoustumourstypicallyexhibitincreasedcellularity,mitoticactivity,andlessfrequentlynuclear
atypia. Therefore, the classiﬁcation within the group of ﬁbromatous tumours may represent some diﬃculties, thus, one or several
of these features should appear. Case. We introduce the clinical and pathologic features based on one case of recurrence of a
mitotically active cellular ovarian ﬁbroma (MACF) in the pararectal fossa. This recurrence took place six years after primary
surgery. Macroscopically, the tumour was ﬁrm, ﬁbrous, well delimited, yellow-white without gross necrosis. On microscopic
examination, it was composed of a densely cellular proliferation of ﬁbrolastic-like cells with bland nuclear features and arranged
in a fascicular pattern. There was no sign of signiﬁcant atypia or necrosis. Conclusion. Recently, this case is the ﬁrst report of a
recurrence of MACF, following primary surgery with no tumoral rupture or surgical diﬃculty. The clinical outcome of ovarian
cellular ﬁbromas (CFs) and MACFs is typically uneventful. This case, however, strongly suggests maintaining a long-term clinical
follow-up even though the principal tumour was surgically treated without tumour rupture or in the absence of adherence or any
surgical diﬃculty.
Copyright © 2009 Dario Bucella et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.CaseReport
A 65-year-old woman looked for assistance to the gyneco-
logical consultation due to recent pelvic pain. Five years
earlier, she went through a total hysterectomy with bilateral
salpingoophorectomy for a benign ovarian mass described as
an ovarian ﬁbroma which eventually happened to be 10cm
long.
The gynecological exam did not show any mass, the
vaginal cuﬀ was soft and not tender. A vaginal ultrasound
and a CT scan highlighted a pelvic mass of 10cm in the
p o u c ho fD o u g l a sa n dr e v e a l e dn oe v i d e n c eo fa d e n o p a t h y .
A laparoscopic exploration of abdominal cavity was per-
formed. This pointed out a large mass in the Douglas while
no other lesion inside the cavity was seen. Subsequently, the
masswasresectedandproperlyextractedinanendobag.Due
to its very low position in the pelvis and to the hemorrhage,
the resection could not be completed. Macroscopically, the
tumour (12 × 10 × 9cm) was ﬁrm, ﬁbrous, well delim-
ited, yellow-white without gross necrosis. On microscopic
examination, it was made of a densely cellular proliferation
of ﬁbrolastic-like cells with bland nuclear features and
arranged in a fascicular pattern. No signiﬁcant atypia or
necrosis could be observed. The tumoral cells were highly
immunoreactive for vimentin and focally for alpha-inhibin,
actinandCD99.Desmin,h-caldesmon,CD10,HMB-45,and
c-kit were negative. The mitotic index was estimated at 4
mitoses/10 HPFs and the ki-67 index at 9%. After reviewing
the slides concerning the primitive ovarian tumour, these
presented similar morphological and immunohistochemical
features.
Based on the above, it was hence decided to diagnose a
recurrence of mitotically active cellular ﬁbroma of the ovary
(MACF). Six months later, the patient was diagnosed with
a new recurrence which mass was 8cm long and situated
in the right pararectal region. The patient went though an
MRI which later conﬁrmed the recurrence of the mass. A
laparotomy was then performed with a large resection of the
pararectal recurrence (Figure 1). The pathological ﬁndings
of this lesion were similar to the ﬁrst recurrence description2 Obstetrics and Gynecology International
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Figure 1: Recurring MECF macroscopic ﬁndings. Regular, lobu-
lated, ﬁrm, and ﬁbrous yellow-white tumours.
Figure 2: Microscopically, the tumour was composed of a dense
proliferation of spindle cells, shaped cells with bland nuclei, and
without no more mild cytological atypia. Note the presence of
mitotic ﬁgures. Haematoxylin-eosin, X40.
(Figure 2). It was decided to prescribe the patient with
Tamoxifen (20mg) on a daily basis and to schedule a long-
term clinical follow-up. Six months after the surgery, no sign
of new recurrence was noted.
2. Discussion
We present the clinical and pathologic features over one
case of recurrence of a mitotically active cellular ovarian
ﬁbroma. This speciﬁc type of histological characteristic
is rare. Ovarian stromal tumours composed of a pure
proliferation of ﬁbroblastic cells usually consist of ﬁbromas,
cellular ﬁbromas (CFs), and hardly ever of ﬁbrosarcomas.
The majority of these neoplasms are benign ﬁbromas with
appreciable intercellular collagen, nonstriking cellularity,
bland nuclei, and rare to absent mitotic ﬁgures (MFs).
About 10% of ﬁbromatous tumours exhibit increased
cellularity,mitoticactivity,andlessfrequentlynuclearatypia.
It is then diﬃcult to classify a case within the group of
ﬁbromatous tumours when one or several of these features
exist.
In 1981, Prat and Scully suggested histological criteria
for the distinction of CFs from ﬁbrosarcomas based on a
study including the analysis of 17 diﬀerent cases [1]. This
distinction was based on cellular proliferations of ﬁbroblasts,
nuclear atypia, mitotic count of 3 or fewer MFs per 10 high-
power ﬁelds (MFs/10 HPFs) and malignant potential. For
theseauthors,ﬁbrosarcomaoftenexhibitsmoderatetosevere
nuclear atypia, mitotic counts of 4 or more MFs/10 HPFs,
and a clinically malignant course. The opposite features were
typical of CFs.
More recently, a study from Irving et al. reviewed 75
cases of ovarian CFs [2]. They all had poor features (cellular
proliferations of ﬁbroblasts, nuclear atypia, and a clinical
malignant potential behaviour) except for the presence of
signiﬁcant mitotic rate. Thirty ﬁve cases presented 0 to
3 mitoses/10 HPFs and were classiﬁed as CFs. The mean age
of patients was 51 years. The following 40 cases presented
≥4 mitoses/10 HPFs and were classiﬁed as MACFs. The
mean age was 41 years.
No data about follow-up were highlighted for patients
presentingCFsthoughthesehappenedtobementionedwith
regard to patients presenting MACFs. Finally, this study did
not refer to any recurrence for patients with MACFs.
Since the ﬁrst study published by Prat and Scully in 1981,
a number of ovarian ﬁbrosarcomas with a benign clinical
course have been reported in the literature in which the
diagnosis was based primarily or exclusively on a mitotic
rate of 4 or more MFs/10 HPFs [3–11]. In those papers,
only the 4 MFs/10 HPFs were taken into account to make
the diﬀerence between CFs and ﬁbrosarcomas. The later
classiﬁcation introduced in 2006 by Irving et al. of CFs was
based on mitotic rate but also insisted on the fact that other
histological and clinical features might explain the multitude
of reports of ovarian ﬁbrosarcomas with no recurrence after
surgery. Irving et al. reviewed and reclassiﬁed those reports
into MACFs. Recently, a new report of an MACF showed no
e v i d e n c eo fr e c u r r e n c ea f t e r1 - y e a rf o l l o w - u pa f t e rs u r g e r y
[12].
Accordingtothisclassiﬁcation,reviewofliteratureshows
that only 2 cases of recurrence of MACFs have been reported
[1]. Both patients with recurrences died in the following
years. The ﬁrst patient presented a primary ovarian tumour
adherent to the pelvic wall and omentum, and the patient
died of recurrent disease 2.75 years later. During primary
surgery for the second patient, the ovarian tumour was
ruptured. The patient died of unrelated causes and autopsy
later conﬁrmed the existence of a recurrent tumour.
Our case shows a recurrence 5 years following primary
surgery. The ﬁrst surgical intervention was performed with-
out any problem hence no adhesiolysis was necessary and the
ovariantumourwasextractedwithoutrupture.Ourreportis
the ﬁrst to present a late recurrence of MACF after primary
surgery which was previously performed with no tumoral
rupture or surgical diﬃculty.
The clinical outcome of ovarian CFs and MACFs is
typically uneventful, but this report strongly suggests long-
term clinical follow-up even if primary tumour was surgi-
cally treated without rupture or in absence of adherence or
surgical diﬃculty.Obstetrics and Gynecology International 3
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